Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Hepatitis

Free Subscription Articles published in Clin Infect Dis Retrieve available abstracts of 225 articles: HTML format

Single Articles

July 2021
1. IJAZ S, Derrick J, Shute J, Ireland G, et al
   Mother To Infant Transmission Of Hepatitis B Virus In The Face Of Neonatal Immunisation Is Not Necessarily Primary Vaccine Failure.
   Clin Infect Dis. 2021 Jul 12. pii: 6319332. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2021
2. BARTLETT SR, Wong S, Yu A, Pearce M, et al
   The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study.
   Clin Infect Dis. 2021 Jun 14. pii: 6298569. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. VALERIO H, Alavi M, Law M, McManus H, et al
   Opportunities to enhance linkage to hepatitis C care among hospitalised people with recent drug dependence in New South Wales, Australia: A population-based linkage study.
   Clin Infect Dis. 2021 Jun 9. pii: 6295650. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. ONOFRIO FQ, Cooper C, Borgia SM, Vachon ML, et al
   Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
   Clin Infect Dis. 2021;72:e799-e805.
   PubMed     Abstract available
   
   
   May 2021
5. BOEKE CE, Hiebert L, Waked I, Tsertsvadze T, et al
   Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries.
   Clin Infect Dis. 2021 May 20. pii: 6279051. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. TOY M, Hutton D, Harris AM, Nelson N, et al
   Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
   Clin Infect Dis. 2021 May 6. pii: 6270943. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2021
7. HEO M, Pericot-Valverde I, Rennert L, Akiyama MJ, et al
   Hepatitis C virus DAA treatment adherence patterns and SVR among people who inject drugs treated in opioid agonist therapy programs.
   Clin Infect Dis. 2021 Apr 20. pii: 6238636. doi: 10.1093.
   PubMed     Abstract available
   
   
   
8. MERAT S, Sharifi AH, Poustchi H, Hajiani E, et al
   Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase III Clinical Trial.
   Clin Infect Dis. 2021 Apr 15. pii: 6226813. doi: 10.1093/cid/ciaa1768.
   PubMed    
   
   
   
9. LEE SK, Sung PS, Park SS, Min CK, et al
   Reactivation of resolved hepatitis B after daratumumab for multiple myeloma.
   Clin Infect Dis. 2021 Apr 13. pii: 6224403. doi: 10.1093.
   PubMed     Abstract available
   
   
   March 2021
10. FACENTE SN, Patel S, Hecht J, Wilson E, et al
    Hepatitis C care cascades for three populations at high risk: low-income trans women, young people who inject drugs, and men who have sex with men and inject drugs.
    Clin Infect Dis. 2021 Mar 26. pii: 6188771. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. CASSEB J, Marcusso RMN, Monteiro M, Assone T, et al
    Human T-Cell Lymphotropic Virus/Human Immunodeficiency Virus, and Hepatitis C Virus Coinfection: Clinical Outcomes After 22 Years of Follow-up in Sao Paulo City.
    Clin Infect Dis. 2021 Mar 2. pii: 6156779. doi: 10.1093/cid/ciaa1008.
    PubMed    
    
    
    February 2021
12. SPRADLING PR, Zhong Y, Moorman AC, Rupp LB, et al
    The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017.
    Clin Infect Dis. 2021 Feb 9. pii: 6131867. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. TAMAKI N, Kurosaki M, Yasui Y, Mori N, et al
    Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
    Clin Infect Dis. 2021 Feb 5. pii: 6129141. doi: 10.1093/cid/ciaa1307.
    PubMed     Abstract available
    
    
    January 2021
14. LIU L, Wang L, Zhang H, Ou W, et al
    Changing Epidemiology of HBV and HCV Co-Infection in HIV-Positive Population in China: Results from the Third and Fourth Nationwide Molecular Epidemiologic Surveys.
    Clin Infect Dis. 2021 Jan 27. pii: 6121253. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. YAYA I, Dembele Keita B, Anoma C, Dah TTE, et al
    Low Seroprevalence of Hepatitis C Among Men Who Have Sex With Men in West Africa.
    Clin Infect Dis. 2021 Jan 25. pii: 6119726. doi: 10.1093.
    PubMed    
    
    
    
16. SONG DS, Jang JW, Yoo SH, Kwon JH, et al
    Improving the prediction of relapse after nucleos(t)ide analogue discontinuation in patients with chronic hepatitis B.
    Clin Infect Dis. 2021 Jan 8. pii: 6071005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. COTTE L, Hocqueloux L, Lefebvre M, Pradat P, et al
    Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018.
    Clin Infect Dis. 2021 Jan 5. pii: 6064641. doi: 10.1093/cid/ciaa1940.
    PubMed     Abstract available
    
    
    
18. ZENG QL, Yu ZJ, Ji F, Li GM, et al
    Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
    Clin Infect Dis. 2021 Jan 4. pii: 6062485. doi: 10.1093/cid/ciaa1939.
    PubMed     Abstract available
    
    
    December 2020
19. IRVIN R, Gamble T, Malone J, Wang Z, et al
    HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status.
    Clin Infect Dis. 2020 Dec 21. pii: 6042798. doi: 10.1093/cid/ciaa1869.
    PubMed     Abstract available
    
    
    
20. HAI VV, Shimakawa Y, Kim J, Do Ngoc H, et al
    Assessment and simplification of treatment eligibility among patients with chronic hepatitis B infection in Vietnam.
    Clin Infect Dis. 2020 Dec 17. pii: 6040789. doi: 10.1093/cid/ciaa1814.
    PubMed     Abstract available
    
    
    
21. KOOPSEN J, Parker E, Han AX, van de Laar T, et al
    HCV transmission among MSM in Amsterdam: external introductions may complicate micro-elimination efforts.
    Clin Infect Dis. 2020 Dec 8. pii: 6025521. doi: 10.1093/cid/ciaa1830.
    PubMed     Abstract available
    
    
    
22. VINIKOOR MJ
    TREAT-B: simple low-cost diagnostic score for when to treat hepatitis B.
    Clin Infect Dis. 2020 Dec 4. pii: 6024449. doi: 10.1093/cid/ciaa1820.
    PubMed    
    
    
    November 2020
23. CORMA-GOMEZ A, Macias J, Morano L, Rivero A, et al
    Liver stiffness-based strategies predict absence of variceal bleeding in cirrhotic HCV-infected patients with and without HIV-coinfection after sustained virological response.
    Clin Infect Dis. 2020 Nov 19. pii: 5992241. doi: 10.1093/cid/ciaa1726.
    PubMed     Abstract available
    
    
    October 2020
24. ESAULENKO EV, Yakovlev AA, Volkov GA, Sukhoruk AA, et al
    Efficacy and Safety of a 3-Antigen (Pre-S1/Pre-S2/S) Hepatitis B Vaccine: Results of a Phase 3 randomized clinical trial in the Russian Federation.
    Clin Infect Dis. 2020 Oct 29. pii: 5942941. doi: 10.1093/cid/ciaa1649.
    PubMed     Abstract available
    
    
    
25. DOYLE JS, van Santen DK, Iser D, Sasadeusz J, et al
    Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
    Clin Infect Dis. 2020 Oct 3. pii: 5917707. doi: 10.1093/cid/ciaa1500.
    PubMed     Abstract available
    
    
    
26. LIU CH, Kao JH
    Last Mile to Microelimination of HCV Infection among People Living with HIV.
    Clin Infect Dis. 2020 Oct 1. pii: 5917174. doi: 10.1093/cid/ciaa1499.
    PubMed    
    
    
    September 2020
27. PLUMB ID, Gounder PP, Nolen LD, Massay SC, et al
    Vaccination Status of Alaska Native Persons With Hepatitis A Virus Infection-Alaska, 1996-2018.
    Clin Infect Dis. 2020 Sep 24. pii: 5910738. doi: 10.1093/cid/ciaa1102.
    PubMed     Abstract available
    
    
    
28. CARRERO A, Berenguer J, Hontanon V, Guardiola JM, et al
    Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients.
    Clin Infect Dis. 2020 Sep 15. pii: 5905898. doi: 10.1093/cid/ciaa1396.
    PubMed     Abstract available
    
    
    
29. GINDIN Y, Gaggar A, Lok AS, Janssen HLA, et al
    DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV or HCV, with or without HIV Co-Infection.
    Clin Infect Dis. 2020 Sep 11. pii: 5904184. doi: 10.1093/cid/ciaa1371.
    PubMed     Abstract available
    
    
    
30. SULKOWSKI M, Wyles D
    Deja vu all over again: retreatment of HCV DAA failures- same satisfactory results, same unanswered questions.
    Clin Infect Dis. 2020 Sep 5. pii: 5901659. doi: 10.1093/cid/ciaa1329.
    PubMed    
    
    
    
31. PAPALUCA T, Roberts SK, Strasser SI, Stuart KA, et al
    Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
    Clin Infect Dis. 2020 Sep 5. pii: 5901660. doi: 10.1093/cid/ciaa1318.
    PubMed     Abstract available
    
    
    
32. KHALILI M, King WC, Kleiner DE, Jain MK, et al
    Fatty Liver Disease in a Prospective North American Cohort of Adults with HIV and Hepatitis B Coinfection.
    Clin Infect Dis. 2020 Sep 1. pii: 5900012. doi: 10.1093/cid/ciaa1303.
    PubMed     Abstract available
    
    
    August 2020
33. PAN CQ
    The role of earlier use of immunoprophylaxis in preventing mother to child transmission of hepatitis B.
    Clin Infect Dis. 2020 Aug 20. pii: 5895015. doi: 10.1093/cid/ciaa1226.
    PubMed    
    
    
    
34. CORMA-GOMEZ A, Macias J, Lacalle-Remigio JR, Tellez F, et al
    HIV infection is associated with lower risk of hepatocellular carcinoma after sustained virological response to direct-acting antivirals in hepatitis C infected-patients with advanced fibrosis.
    Clin Infect Dis. 2020 Aug 7. pii: 5885174. doi: 10.1093/cid/ciaa1111.
    PubMed     Abstract available
    
    
    
35. BRAUN DL, Hampel B, Ledergerber B, Grube C, et al
    A treatment as prevention trial to eliminate hepatitis C among men who have sex with men living with HIV in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2020 Aug 6. pii: 5881825. doi: 10.1093/cid/ciaa1124.
    PubMed     Abstract available
    
    
    
36. ROCKSTROH JK
    Hepatitis C (HCV) microelimination in HIV-coinfected men who have sex with men (MSM): A low hanging fruit?
    Clin Infect Dis. 2020 Aug 5. pii: 5881444. doi: 10.1093/cid/ciaa1113.
    PubMed    
    
    
    
37. GIBNEY KB, MacLachlan J, Coutts R, Higgins N, et al
    Incidence of invasive pneumococcal disease higher among people notified with markers of hepatitis C virus infection: Population-based surveillance in Victoria, Australia 2001-2017.
    Clin Infect Dis. 2020 Aug 4. pii: 5880584. doi: 10.1093/cid/ciaa1110.
    PubMed     Abstract available
    
    
    July 2020
38. ANDERSON M, Gersch J, Luk KC, Dawson G, et al
    Circulating Pregenomic HBV RNA is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue Therapy.
    Clin Infect Dis. 2020 Jul 20. pii: 5873731. doi: 10.1093/cid/ciaa1015.
    PubMed     Abstract available
    
    
    
39. TAN BK, Chalouni M, Ceron DS, Cinaud A, et al
    Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.
    Clin Infect Dis. 2020 Jul 20. pii: 5873715. doi: 10.1093/cid/ciaa1014.
    PubMed     Abstract available
    
    
    
40. GIANNINI EG, Bodini G, Marabotto E, Furnari M, et al
    Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients.
    Clin Infect Dis. 2020 Jul 13. pii: 5870725. doi: 10.1093.
    PubMed    
    
    
    
41. FELD JJ, Matthews GV
    Don't wait: The benefits of early diagnosis in perinatal HCV transmission.
    Clin Infect Dis. 2020 Jul 8. pii: 5868960. doi: 10.1093.
    PubMed    
    
    
    
42. GOWDA C, Smith S, Crim L, Moyer K, et al
    Nucleic Acid Testing for Diagnosis of Perinatally-Acquired Hepatitis C Virus Infection in Early Infancy.
    Clin Infect Dis. 2020 Jul 8. pii: 5868931. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. HUANG H, Xu C, Liu L, Chen L, et al
    Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus.
    Clin Infect Dis. 2020 Jul 8. pii: 5868509. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2020
44. HUNG IF, Yap DY, Yip TP, Zhang RR, et al
    A double-blind randomized phase 2 controlled trial of intradermal hepatitis B vaccination with a topical Toll-like receptor 7 agonist imiquimod, in patients on dialysis.
    Clin Infect Dis. 2020 Jun 18. pii: 5859563. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. LAI JC, Wong VW, Wong GL
    Reply to Sun et al.
    Clin Infect Dis. 2020;70:2748-2749.
    PubMed    
    
    
    
46. NSANZIMANA S, Penkunas MJ, Liu CY, Sebuhoro D, et al
    Effectiveness of Direct-Acting Antivirals for the treatment of chronic hepatitis C in Rwanda: A retrospective study.
    Clin Infect Dis. 2020 Jun 6. pii: 5854316. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. ROCKSTROH JK
    Non-invasive markers for monitoring fibrosis regression after HCV-cure: what do they promise?
    Clin Infect Dis. 2020 Jun 5. pii: 5854050. doi: 10.1093.
    PubMed    
    
    
    
48. ANUGWOM CM, Aby ES, Debes JD
    Inverse association between chronic hepatitis B infection and COVID-19: immune-exhaustion or coincidence?
    Clin Infect Dis. 2020 Jun 5. pii: 5851928. doi: 10.1093.
    PubMed    
    
    
    
49. KRONFLI N, Young J, Wang S, Cox J, et al
    Liver fibrosis in HIV-Hepatitis C virus (HCV) co-infection before and after sustained virologic response: what is the best non-invasive marker for monitoring regression?
    Clin Infect Dis. 2020 Jun 5. pii: 5854053. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. CHANCHAROENTHANA W, Leelahavanichkul A
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Benefits and Risks.
    Clin Infect Dis. 2020 Jun 3. pii: 5850914. doi: 10.1093.
    PubMed    
    
    
    May 2020
51. NEWSUM AM, Matser A, Schinkel J, van der Valk M, et al
    Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis.
    Clin Infect Dis. 2020 May 27. pii: 5847810. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. ABDEL-HAMEED EA, Rouster SD, Kottilil S, Sherman KE, et al
    The enhanced liver fibrosis (ELF)-Index predicts hepatic fibrosis superior to FIB4 and APRI in HIV/HCV infected patients.
    Clin Infect Dis. 2020 May 27. pii: 5847812. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. HELLARD M, Drummer H, Scott N
    Striving for hepatitis C elimination - the role of a vaccine.
    Clin Infect Dis. 2020 May 25. pii: 5843664. doi: 10.1093.
    PubMed    
    
    
    
54. GREBELY J, Tran L, Degenhardt L, Dowell-Day A, et al
    Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis.
    Clin Infect Dis. 2020 May 24. pii: 5843586. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. KATTAKUZHY S, Rosenthal E
    To Eliminate Hepatitis C in People Who Inject Drugs, Stop Ignoring Drug User Health.
    Clin Infect Dis. 2020 May 23. pii: 5843471. doi: 10.1093.
    PubMed    
    
    
    
56. COX A, Sulkowski M, Sugarman J
    Ethical and Practical Issues Associated with the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine.
    Clin Infect Dis. 2020 May 22. pii: 5842210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. VALERIO H, Alavi M, Silk D, Treloar C, et al
    Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study.
    Clin Infect Dis. 2020 May 18. pii: 5838577. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. SETH A, Sherman KE
    Editorial: HCV Cure is the Start of the End For Those With Advanced Fibrosis/Cirrhosis.
    Clin Infect Dis. 2020 May 9. pii: 5835187. doi: 10.1093.
    PubMed    
    
    
    
59. DIEZ C, Berenguer J, Ibanez-Samaniego L, Llop E, et al
    Persistence of clinically significant portal hypertension after eradication of HCV in patients with advanced cirrhosis.
    Clin Infect Dis. 2020 May 9. pii: 5835009. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2020
60. CHAILLON A, Wynn A, Kushner T, Reau N, et al
    Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
    Clin Infect Dis. 2020 Apr 13. pii: 5819607. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. WONG CY, Zhu W, Aurigemma GP, Furukawa N, et al
    Infective endocarditis among persons aged 18-64 years with HIV, hepatitis C infection, or opioid use disorder - United States, 2007-2017.
    Clin Infect Dis. 2020 Apr 9. pii: 5818223. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. ZHAO J, Liao X, Wang H, Wei L, et al
    Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV.
    Clin Infect Dis. 2020 Apr 9. pii: 5818121. doi: 10.1093.
    PubMed     Abstract available
    
    
    
63. DORE GJ, Cowie B
    Global Hepatitis B Virus Elimination by 2030: China Is Pivotal and Instructive.
    Clin Infect Dis. 2020 Apr 7. pii: 5817060. doi: 10.1093.
    PubMed    
    
    
    
64. NAYAGAM S, Chan P, Zhao K, Sicuri E, et al
    Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
    Clin Infect Dis. 2020 Apr 7. pii: 5817057. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2020
65. GARVEY LJ, Cooke GS, Smith C, Stingone C, et al
    Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?
    Clin Infect Dis. 2020 Mar 25. pii: 5811003. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. YIN S, Barker L, Ly KN, Kilmer G, et al
    Susceptibility to Hepatitis A Virus Infection in the United States, 2007-2016.
    Clin Infect Dis. 2020 Mar 20. pii: 5810334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. BAROCAS JA
    It's not them, it's us: Hepatitis C reinfection following successful treatment among people who inject drugs.
    Clin Infect Dis. 2020 Mar 12. pii: 5804221. doi: 10.1093.
    PubMed    
    
    
    
68. CUNNINGHAM EB, Hajarizadeh B, Amin J, Hellard M, et al
    Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.
    Clin Infect Dis. 2020 Mar 12. pii: 5804220. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. BACH P, Ti L
    Hepatitis C and Stimulant use Disorder: Challenges and Opportunities.
    Clin Infect Dis. 2020 Mar 12. pii: 5803334. doi: 10.1093.
    PubMed    
    
    
    February 2020
70. WANG XD, Liu JP, Song TR, Huang ZL, et al
    Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.
    Clin Infect Dis. 2020 Feb 26. pii: 5758069. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. TERRAULT N
    Transplanting Kidneys from Donors with Chronic Hepatitis B: Bringing Transmission Risk Closer to Zero.
    Clin Infect Dis. 2020 Feb 25. pii: 5755200. doi: 10.1093.
    PubMed    
    
    
    
72. ZELENEV A, Li J, Shea P, Hecht R, et al
    Modeling Combination HCV Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the USA.
    Clin Infect Dis. 2020 Feb 15. pii: 5736406. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. MARCELLIN F, Miailhes P, Santos M, Mercie P, et al
    Cannabis use and plasma HIV RNA levels in HIV-HCV co-infected patients receiving antiretroviral therapy: data from the ANRS CO13 HEPAVIH cohort.
    Clin Infect Dis. 2020 Feb 14. pii: 5735646. doi: 10.1093.
    PubMed    
    
    
    
74. POPPING S, Verwijs R, Cuypers L, Claassen M, et al
    Transmission of NS5A resistance associated substitutions among men-who-have-sex-with-men recently infected with hepatitis C virus genotype 1a.
    Clin Infect Dis. 2020 Feb 14. pii: 5735665. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. LOK AS
    Is Sustained Virologic Response to Direct-Acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?
    Clin Infect Dis. 2020 Feb 13. pii: 5734995. doi: 10.1093.
    PubMed    
    
    
    
76. KRASSENBURG LAP, Zanjir WR, Georgie F, Stotland E, et al
    Evaluation of sustained virological response as a relevant surrogate endpoint for long-term outcomes of hepatitis C virus infection.
    Clin Infect Dis. 2020 Feb 13. pii: 5734994. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. SPRINGER SA, Del Rio C
    Co-located opioid use disorder and HCV treatment is not only right but it is also the smart thing to do as it improves outcomes!
    Clin Infect Dis. 2020 Feb 3. pii: 5721551. doi: 10.1093.
    PubMed    
    
    
    
78. ROSENTHAL ES, Silk R, Mathur P, Gross C, et al
    Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.
    Clin Infect Dis. 2020 Feb 3. pii: 5721142. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2020
79. PATEL EU, Mehta SH, Boon D, Quinn TC, et al
    Reply to MacDonald et al.
    Clin Infect Dis. 2020;70:544-545.
    PubMed    
    
    
    
80. FARAG MS, van Campenhout MJH, Pfefferkorn M, Fischer J, et al
    Hepatitis B virus RNA as Early Predictor for Response to PEGylated Interferon Alfa in HBeAg Negative Chronic Hepatitis B.
    Clin Infect Dis. 2020 Jan 8. pii: 5698122. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2019
81. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    
    
    
    
82. BUTT AA, Yan P, Aslam S, Abou-Samra AB, et al
    Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES.
    Clin Infect Dis. 2019 Dec 16. pii: 5678676. doi: 10.1093/cid/ciz1097.
    PubMed     Abstract available
    
    
    
83. SINGH KP, Lewin SR
    Hepatitis B infection in people living with HIV - a global challenge needing more research.
    Clin Infect Dis. 2019 Dec 9. pii: 5669954. doi: 10.1093/cid/ciz1175.
    PubMed    
    
    
    
84. LEUMI S, Bigna JJ, Amougou MA, Ngouo A, et al
    Global burden of hepatitis B infection in people living with HIV: a systematic review and meta-analysis.
    Clin Infect Dis. 2019 Dec 9. pii: 5669955. doi: 10.1093/cid/ciz1170.
    PubMed     Abstract available
    
    
    
85. KAMAR N, Abravanel F, Behrendt P, Hofmann J, et al
    Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study.
    Clin Infect Dis. 2019 Dec 3. pii: 5650877. doi: 10.1093.
    PubMed     Abstract available
    
    
    
86. CRUM-CIANFLONE NF
    Therapy for Chronic Hepatitis E Virus Infection-Current Recommendations and Future Aspirations.
    Clin Infect Dis. 2019 Dec 3. pii: 5650876. doi: 10.1093.
    PubMed    
    
    
    November 2019
87. OGAWA E, Toyoda H, Iio E, Jun DW, et al
    HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication.
    Clin Infect Dis. 2019 Nov 28. pii: 5645107. doi: 10.1093/cid/ciz1160.
    PubMed     Abstract available
    
    
    
88. CORMA-GOMEZ A, Macias J, Tellez F, Freyre-Carrillo C, et al
    Liver stiffness at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected patients with advanced fibrosis treated with direct-acting antivirals.
    Clin Infect Dis. 2019 Nov 22. pii: 5637523. doi: 10.1093/cid/ciz1140.
    PubMed     Abstract available
    
    
    
89. CUNNINGHAM EB, Hajarizadeh B, Amin J, Litwin AH, et al
    Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.
    Clin Infect Dis. 2019 Nov 2. pii: 5611150. doi: 10.1093/cid/ciz1089.
    PubMed     Abstract available
    
    
    October 2019
90. SCHULTE B, Schmidt CS, Strada L, Rosenkranz M, et al
    Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
    Clin Infect Dis. 2019 Oct 21. pii: 5601291. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. LIN KY, Lee YL, Huang SH, Chen GJ, et al
    Public health intervention strategies to contain hepatitis A outbreak.
    Clin Infect Dis. 2019 Oct 14. pii: 5586740. doi: 10.1093/cid/ciz1002.
    PubMed    
    
    
    
92. MERAT S
    Erratum to: SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
    Clin Infect Dis. 2019 Oct 12. pii: 5586681. doi: 10.1093.
    PubMed    
    
    
    
93. LY KN, Minino AM, Liu SJ, Roberts H, et al
    Deaths Associated with Hepatitis C Virus Infection among Residents in 50 States and the District of Columbia, 2016-2017.
    Clin Infect Dis. 2019 Oct 5. pii: 5581721. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. MARTINELLO M, Yee J, Bartlett SR, Read P, et al
    Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
    Clin Infect Dis. 2019 Oct 4. pii: 5581531. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2019
95. TSERTSVADZE T, Gamkrelidze A, Chkhartishvili N, Abutidze A, et al
    Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018.
    Clin Infect Dis. 2019 Sep 29. pii: 5575959. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. FALADE-NWULIA O
    HCV Elimination requires more than Good Drugs.
    Clin Infect Dis. 2019 Sep 29. pii: 5575956. doi: 10.1093.
    PubMed    
    
    
    
97. CHROMY D, Schmidt R, Mandorfer M, Lang GF, et al
    HCV-RNA is commonly detectable in rectal and nasal fluids of patients with high viremia.
    Clin Infect Dis. 2019 Sep 28. pii: 5575905. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. INGILIZ P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, et al
    Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era.
    Clin Infect Dis. 2019 Sep 28. pii: 5575902. doi: 10.1093.
    PubMed     Abstract available
    
    
    
99. GRAF C, Mucke MM, Dultz G, Peiffer KH, et al
    Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2019 Sep 12. pii: 5568364. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. NORTON BL, Litwin AH
     A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
     Clin Infect Dis. 2019 Sep 12. pii: 5568312. doi: 10.1093.
     PubMed    
     
     
     August 2019
101. SAEED S, Strumpf E, Moodie EEM, Wong L, et al
     Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV.
     Clin Infect Dis. 2019 Aug 28. pii: 5555890. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. MCMAHON BJ, Townshend-Bulson L, Homan C, Gounder P, et al
     Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care.
     Clin Infect Dis. 2019 Aug 28. pii: 5555891. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. KOIBUCHI T, Koga M, Kikuchi T, Horikomi T, et al
     Prevalence of hepatitis A immunity and decision-tree analysis among HIV-infected men who have sex with men, in Tokyo.
     Clin Infect Dis. 2019 Aug 26. pii: 5554745. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. KUSHNER T, Chen Z, Tressler S, Kaufman H, et al
     Trends in Hepatitis B Infection and Immunity among Women of Childbearing Age in the United States.
     Clin Infect Dis. 2019 Aug 26. pii: 5554743. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. SEROTA DP, Barocas JA, Springer SA
     Infectious complications of addiction: A call for a new subspecialty within infectious diseases.
     Clin Infect Dis. 2019 Aug 17. pii: 5550920. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. PEAK CM, Stous SS, Healy JM, Hofmeister MG, et al
     Homelessness and Hepatitis A - San Diego County, 2016-2018.
     Clin Infect Dis. 2019 Aug 15. pii: 5550168. doi: 10.1093.
     PubMed     Abstract available
     
     
     
107. STEVENS ER, Nucifora KA, Hagan H, Jordan AE, et al
     Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.
     Clin Infect Dis. 2019 Aug 11. pii: 5546014. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. SUN L, Fan J, Gao H, Shan L, et al
     Background End-stage Liver Diseases but not Pure HBV Infection Exacerbate Clinical Outcomes in Patients with Acute Hepatitis E.
     Clin Infect Dis. 2019 Aug 1. pii: 5542442. doi: 10.1093.
     PubMed    
     
     
     July 2019
109. SAFREED-HARMON K, Blach S, Aleman S, Boe Kielland K, et al
     The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination.
     Clin Infect Dis. 2019 Jul 28. pii: 5540024. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. SHING JZ, Ly KN, Xing J, Teshale EH, et al
     Prevalence of Hepatitis B Virus Infection among US Adults Aged 20-59 Years with a History of Injection Drug Use: National Health and Nutrition Examination Survey, 2001-2016.
     Clin Infect Dis. 2019 Jul 27. pii: 5539881. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. AKIYAMA MJ, Lipsey D, Heo M, Agyemang L, et al
     Low Hepatitis C Reinfection Following Direct-Acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
     Clin Infect Dis. 2019 Jul 26. pii: 5538954. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. SPRINGER SA
     HCV reinfection is low among persons who use drugs maintained on medication treatment for Opioid Use Disorder.
     Clin Infect Dis. 2019 Jul 26. pii: 5538956. doi: 10.1093.
     PubMed    
     
     
     
113. ARTENIE AA, Cunningham EB, Dore GJ, Conway B, et al
     Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international s
     Clin Infect Dis. 2019 Jul 11. pii: 5531892. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. MERAT S
     SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial.
     Clin Infect Dis. 2019 Jul 10. pii: 5531032. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. COOPER C
     Eliminating Hepatitis C (and the Unknowns) in the HIV Co-Infected.
     Clin Infect Dis. 2019 Jul 2. pii: 5527234. doi: 10.1093.
     PubMed    
     
     
     
116. MOCROFT A, Lundgren J, Gerstoft J, Rasmussen LD, et al
     Clinical Outcomes in Persons Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus: Impact of Hepatitis C Virus Treatment.
     Clin Infect Dis. 2019 Jul 2. pii: 5527213. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2019
117. WADE AJ, Doyle JS, Gane E, Stedman C, et al
     Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
     Clin Infect Dis. 2019 Jun 22. pii: 5522438. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. KING H, Xing J, Dean HD, Holtzman D, et al
     Trends in prevalence of protective levels of hepatitis B surface antibody among adults aged 18-49 years with risk factors for hepatitis B virus infection-United States, 2003-2014.
     Clin Infect Dis. 2019 Jun 20. pii: 5522094. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. LIN KY, Sun HY, Chen YH, Lo YC, et al
     Effect of a hepatitis A vaccination campaign during a hepatitis A outbreak in Taiwan, 2015-2017: a modeling study.
     Clin Infect Dis. 2019 Jun 3. pii: 5510337. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2019
120. MACDONALD BR, Chu TC, Stewart RA, Ojha RP, et al
     Setting-Based Prioritization for Birth Cohort Hepatitis C Virus Testing in the United States.
     Clin Infect Dis. 2019 May 24. pii: 5498354. doi: 10.1093.
     PubMed    
     
     
     
121. SHIMAKAWA Y, Ndow G, Njie R, Njai HF, et al
     Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa.
     Clin Infect Dis. 2019 May 17. pii: 5491470. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. GUTKIND S, Schackman BR, Morgan JR, Leff JA, et al
     Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
     Clin Infect Dis. 2019 May 16. pii: 5490664. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. ASSOUMOU SA, Tasillo A, Vellozzi C, Yazdi GE, et al
     Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons.
     Clin Infect Dis. 2019 May 16. pii: 5490662. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. HARRINGTON PR, Komatsu TE, Sun H, Naeger LK, et al
     HCV RNA Levels Following Virologic Failure with Direct-Acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
     Clin Infect Dis. 2019 May 10. pii: 5487938. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. TOYODA H, Tada T, Yasuda S, Mizuno K, et al
     Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response.
     Clin Infect Dis. 2019 May 6. pii: 5485915. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2019
126. BUTT AA, Yan P, Aslam S, Shaikh OS, et al
     Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES.
     Clin Infect Dis. 2019 Apr 12. pii: 5448895. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. YOUNOSSI ZM, Stepanova M, Jacobson I, Muir AJ, et al
     Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes.
     Clin Infect Dis. 2019 Apr 5. pii: 5428146. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. BERTISCH B, Brezzi M, Negro F, Mullhaupt B, et al
     Very low hepatitis C viral loads in treatment-naive persons: do they compromise hepatitis C virus antigen testing?
     Clin Infect Dis. 2019 Apr 3. pii: 5426964. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. MATHUR P, Kottilil S
     Hepatitis C core antigen testing: Still an effective diagnostic method for global elimination of hepatitis C.
     Clin Infect Dis. 2019 Apr 3. pii: 5426965. doi: 10.1093.
     PubMed    
     
     
     
130. SORIANO V, Gomez-Gallego F, Corral O
     Hepatitis delta estimates in the United States revisited.
     Clin Infect Dis. 2019 Apr 3. pii: 5426967. doi: 10.1093.
     PubMed    
     
     
     March 2019
131. SALVADORI N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, et al
     Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
     Clin Infect Dis. 2019 Mar 29. pii: 5422240. doi: 10.1093.
     PubMed     Abstract available
     
     
     
132. GANE E, Poordad F, Zadeikis N, Valdes J, et al
     Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
     Clin Infect Dis. 2019 Mar 28. pii: 5421746. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. KISER JJ
     Safety of Hepatitis C Viral Protease Inhibitors in Compensated Cirrhotics: Lingering Concerns Put to Rest?
     Clin Infect Dis. 2019 Mar 28. pii: 5421743. doi: 10.1093.
     PubMed    
     
     
     
134. NAGGIE S, Fierer DS, Hughes MD, Kim AY, et al
     Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
     Clin Infect Dis. 2019 Mar 28. pii: 5421820. doi: 10.1093.
     PubMed     Abstract available
     
     
     
135. LUI GCY, Wong NS, Wong RYK, Tse YK, et al
     Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
     Clin Infect Dis. 2019 Mar 22. pii: 5421304. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2019
136. BOETTIGER DC, Salazar-Vizcaya L, Dore GJ, Gray RT, et al
     Can Australia reach the World Health Organization Hepatitis C elimination goal by 2025 among HIV-positive gay and bisexual men?
     Clin Infect Dis. 2019 Feb 28. pii: 5366676. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. GEDDES L, Iversen J, Wand H, Esmaeili A, et al
     Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection.
     Clin Infect Dis. 2019 Feb 28. pii: 5366653. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. CHEN SH, Lai HC, Chiang IP, Su WP, et al
     Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients with Chronic Hepatitis C after Viral Eradication.
     Clin Infect Dis. 2019 Feb 28. pii: 5366592. doi: 10.1093.
     PubMed     Abstract available
     
     
     
139. RAMIERE C, Charre C, Miailhes P, Bailly F, et al
     Patterns of HCV transmission in HIV-infected and HIV-negative men having sex with men.
     Clin Infect Dis. 2019 Feb 27. pii: 5365873. doi: 10.1093.
     PubMed     Abstract available
     
     
     
140. HEFELE L, Syphan S, Xayavong D, Homsana A, et al
     Seroprotection at different levels of the health care system after routine vaccination with DTPw-HepB-Hib in Lao PDR.
     Clin Infect Dis. 2019 Feb 19. pii: 5335760. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. BROUWER WP, Chan HL, Lampertico P, Hou J, et al
     Genome Wide Association Study Identifies Genetic Variants Associated With Early And Sustained Response To (Peg)Interferon In Chronic Hepatitis B Patients: The GIANT-B Study.
     Clin Infect Dis. 2019 Feb 2. pii: 5305981. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. CHAUDHURY CS, Mee T, Chairez C, McLaughlin M, et al
     Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.
     Clin Infect Dis. 2019 Feb 2. pii: 5305922. doi: 10.1093.
     PubMed     Abstract available
     
     
     
143. BROWN TT
     Hypogonadism in Men With Hepatitis C: What Is a Clinician to Do?
     Clin Infect Dis. 2019 Feb 2. pii: 5305923. doi: 10.1093.
     PubMed    
     
     
     January 2019
144. CHAILLON A, Rand EB, Reau N, Martin NK, et al
     Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States.
     Clin Infect Dis. 2019 Jan 28. pii: 5303781. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. MCAULEY JB, Close R
     Better Guidance on Treating HCV in Pregnancy: The Time is Now.
     Clin Infect Dis. 2019 Jan 7. pii: 5275237. doi: 10.1093.
     PubMed    
     
     
     
146. BRESKIN A, Westreich D, Hurt CB, Cole SR, et al
     The effects of hepatitis C treatment eligibility criteria on all-cause mortality among people with HIV.
     Clin Infect Dis. 2019 Jan 7. pii: 5274661. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. PATEL EU, Thio CL, Boon D, Thomas DL, et al
     Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.
     Clin Infect Dis. 2019 Jan 3. pii: 5272449. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2018
148. LOOMBA R, Decaris M, Li KW, Shankaran M, et al
     Discovery of half-life of circulating HBsAg in patients with chronic hepatitis B infection using heavy water labeling.
     Clin Infect Dis. 2018 Dec 24. pii: 5259172. doi: 10.1093/cid/ciy1100.
     PubMed     Abstract available
     
     
     
149. BENMASSAOUD A, Nitulescu R, Pembroke T, Halme AS, et al
     Liver-related events in HIV-infected persons with occult cirrhosis.
     Clin Infect Dis. 2018 Dec 18. pii: 5251034. doi: 10.1093/cid/ciy1082.
     PubMed     Abstract available
     
     
     October 2018
150. TALAL AH, Andrews P, Mcleod A, Chen Y, et al
     Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone.
     Clin Infect Dis. 2018 Oct 17. pii: 5133592. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. BRESKIN A, Westreich D, Cole SR, Hudgens MG, et al
     The Effects of Hepatitis C Infection and Treatment on All-cause Mortality Among People Living With Human Immunodeficiency Virus.
     Clin Infect Dis. 2018 Oct 12. pii: 5128783. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2018
152. TIO SY, Nickless D, McCracken J, Nedumannil R, et al
     A Man With Tonsillitis and Hepatitis.
     Clin Infect Dis. 2018;67:1303-1305.
     PubMed    
     
     
     
153. LAI JC, Wong GL, Yip TC, Tse YK, et al
     Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016.
     Clin Infect Dis. 2018;67:1278-1284.
     PubMed     Abstract available
     
     
     
154. SHERMAN KE, Abdel-Hameed E, Rouster SD, Shata MTM, et al
     Improvement in Hepatic Fibrosis Biomarkers Associated with Chemokine Receptor Inactivation through Mutation or Therapeutic Blockade.
     Clin Infect Dis. 2018 Sep 20. pii: 5104288. doi: 10.1093.
     PubMed     Abstract available
     
     
     
155. PATEL EU, Mehta SH, Boon D, Quinn TC, et al
     Limited Coverage of Hepatitis C Virus Testing in the United States, 2013-2017.
     Clin Infect Dis. 2018 Sep 15. pii: 5098442. doi: 10.1093.
     PubMed     Abstract available
     
     
     
156. 
     Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
     Clin Infect Dis. 2018 Sep 12. pii: 5095352. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. JHAVERI R, Broder T, Bhattacharya D, Peters MG, et al
     Universal Screening of Pregnant Women for Hepatitis C: The Time Is Now.
     Clin Infect Dis. 2018 Sep 12. pii: 5095353. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2018
158. BUTT AA, Yan P, Lo Re V 3rd, Shaikh OS, et al
     Trends in Treatment Uptake and Provider Specialty for HCV Infection in the VA Healthcare System: Results from ERCHIVES.
     Clin Infect Dis. 2018 Aug 22. pii: 5077936. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. SULKOWSKI MS
     The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
     Clin Infect Dis. 2018 Aug 13. pii: 5071944. doi: 10.1093.
     PubMed    
     
     
     
160. BRAUN DL, Hampel B, Martin E, Kouyos R, et al
     High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men.
     Clin Infect Dis. 2018 Aug 13. pii: 5071946. doi: 10.1093.
     PubMed     Abstract available
     
     
     
161. BRAUN DL, Hampel B, Kouyos R, Nguyen H, et al
     High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
     Clin Infect Dis. 2018 Aug 13. pii: 5071945. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2018
162. BIXLER D, Zhong Y, Ly KN, Moorman AC, et al
     Mortality among Patients with Chronic Hepatitis B (CHB) Infection: the Chronic Hepatitis Cohort Study (CHeCS).
     Clin Infect Dis. 2018 Jul 28. pii: 5061152. doi: 10.1093.
     PubMed     Abstract available
     
     
     
163. SMITH D, Huynh C, Moore AJ, Frick A, et al
     Herd Immunity Likely Protected the Men who have Sex with Men in Recent Hepatitis A Outbreak in San Diego CA.
     Clin Infect Dis. 2018 Jul 25. pii: 5059685. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2018
164. KILMER GA, Barker LK, Ly KN, Jiles RB, et al
     Hepatitis B vaccination and screening among foreign-born women of reproductive age in the United States: 2013-2015.
     Clin Infect Dis. 2018 Jun 1. pii: 5026244. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2018
165. HOSRY J, Angelidakis G, Kaseb A, Jiang Y, et al
     Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study.
     Clin Infect Dis. 2018 May 15. pii: 4996053. doi: 10.1093.
     PubMed    
     
     
     
166. ALROY-PREIS S, Daly ER, Adamski C, Dionne-Odom J, et al
     Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician.
     Clin Infect Dis. 2018 May 14. pii: 4995993. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. MEISSNER EG
     The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?
     Clin Infect Dis. 2018 May 1. pii: 4989914. doi: 10.1093.
     PubMed    
     
     
     
168. INOUE T, Nakayama J, Moriya K, Kawaratani H, et al
     Gut Dysbiosis Associated With Hepatitis C Virus Infection.
     Clin Infect Dis. 2018 May 1. pii: 4989908. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2018
169. HECTOR J, Vinikoor M, Chilengi R, Ehmer J, et al
     No Impact of Hepatitis B Virus Infection on Early Mortality among HIV-infected Patients in Southern Africa.
     Clin Infect Dis. 2018 Apr 18. pii: 4975531. doi: 10.1093.
     PubMed    
     
     
     
170. LEE YL, Chen GJ, Chen NY, Liou BH, et al
     Less Severe but Prolonged Course of Acute Hepatitis A in HIV-positive Patients than HIV-negative Patients During an Outbreak: A Multicenter Observational Study.
     Clin Infect Dis. 2018 Apr 17. pii: 4972863. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. MELLIEZ H, Mary-Krause M, Bocket L, Guiguet M, et al
     Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).
     Clin Infect Dis. 2018 Apr 4. pii: 4960877. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2018
172. WALKER A, Boyce A, Geller G, Thio CL, et al
     Direct Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype.
     Clin Infect Dis. 2018 Mar 29. pii: 4956154. doi: 10.1093.
     PubMed    
     
     
     
173. ROCKSTROH JK, Lacombe K, Viani RM, Orkin C, et al
     Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.
     Clin Infect Dis. 2018 Mar 16. pii: 4939381. doi: 10.1093.
     PubMed     Abstract available
     
     
     
174. BARTLETT SR, Fox P, Cabatingan H, Jaros A, et al
     Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project.
     Clin Infect Dis. 2018 Mar 12. pii: 4930770. doi: 10.1093.
     PubMed     Abstract available
     
     
     
175. KLEINSTEIN SE, Shea PR, Stamm LM, Sulkowski M, et al
     Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
     Clin Infect Dis. 2018 Mar 7. pii: 4705930. doi: 10.1093/cid/cix1051.
     PubMed     Abstract available
     
     
     
176. MOGALIAN E, Stamm LM, Osinusi A, Brainard DM, et al
     Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted HIV Antiretroviral Regimens in Healthy Volunteers.
     Clin Infect Dis. 2018 Mar 7. pii: 4924529. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2018
177. BAROCAS JA, Tasillo A, Eftekhari Yazdi G, Wang J, et al
     Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
     Clin Infect Dis. 2018 Feb 6. pii: 4840186. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2018
178. TROPPY S, Soliva S, Onofrey S, DeMaria A Jr., et al
     Geographic Disparities in Access to Syringe Services Programs Among Young Persons with Hepatitis C Virus Infection in Massachusetts.
     Clin Infect Dis. 2018 Jan 31. pii: 4831117. doi: 10.1093.
     PubMed    
     
     
     December 2017
179. HUA S, Vigano S, Tse S, Zhengyu O, et al
     Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
     Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
     PubMed     Abstract available
     
     
     
180. YOUNOSSI ZM, Stepanova M, Asselah T, Foster G, et al
     Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
     Clin Infect Dis. 2017 Dec 20. pii: 4766885. doi: 10.1093/cid/cix1106.
     PubMed     Abstract available
     
     
     
181. RICKLES M, Rebeiro PF, Sizemore L, Juarez P, et al
     Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic.
     Clin Infect Dis. 2017 Dec 7. pii: 4706246. doi: 10.1093/cid/cix1079.
     PubMed     Abstract available
     
     
     
182. KAPADIA SN, Jeng PJ, Schackman BR, Bao Y, et al
     State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals.
     Clin Infect Dis. 2017 Dec 1. pii: 4682615. doi: 10.1093/cid/cix1062.
     PubMed     Abstract available
     
     
     November 2017
183. BOEREKAMPS A, Newsum AM, Smit C, Arends JE, et al
     High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands.
     Clin Infect Dis. 2017 Nov 23. pii: 4654728. doi: 10.1093/cid/cix1004.
     PubMed     Abstract available
     
     
     
184. ROCKSTROH JK
     Is HCV elimination in well-defined patient groups possible?
     Clin Infect Dis. 2017 Nov 23. pii: 4654730. doi: 10.1093/cid/cix1010.
     PubMed    
     
     
     
185. BOEREKAMPS A, Van den Berk GE, Fanny LN, Leyten EM, et al
     Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
     Clin Infect Dis. 2017 Nov 23. pii: 4654729. doi: 10.1093/cid/cix1007.
     PubMed     Abstract available
     
     
     
186. BEDIMO RJ, Adams-Huet B, Poindexter J, Brown G, et al
     The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.
     Clin Infect Dis. 2017 Nov 14. doi: 10.1093/cid/cix1011.
     PubMed     Abstract available
     
     
     October 2017
187. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
     Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
     Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
     PubMed     Abstract available
     
     
     
188. YAYA I, Costa M, Marcellin F, Miailhes P, et al
     Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
     Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
     PubMed    
     
     
     
189. PARR JB, Lodge EK, Holzmayer V, Pepin J, et al
     An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.
     Clin Infect Dis. 2017 Oct 18. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2017
190. BUTT AA, Yan P, Simon TG, Abou-Samra AB, et al
     Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
     Clin Infect Dis. 2017;65:1006-1011.
     PubMed     Abstract available
     
     
     
191. HASHEM M, Jhaveri R, Saleh DA, Sharaf SA, et al
     Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
     Clin Infect Dis. 2017;65:999-1005.
     PubMed     Abstract available
     
     
     
192. PIROTH L, Launay O, Miailhes P, Carrat F, et al
     Isolated anti-HBc serological profile: has the time come to vaccinate?
     Clin Infect Dis. 2017 Sep 15. doi: 10.1093.
     PubMed    
     
     
     
193. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
     The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
     Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. CHHATWAL J
     Hepatitis C screening: From modeling to public health policy.
     Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
     PubMed    
     
     
     
195. LIU CH, Chen YS, Wang SS, Liu CJ, et al
     Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.
     Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
     PubMed     Abstract available
     
     
     
196. WEINBERG EM, Reddy KR
     Let's Make a Deal: Shortening the solid organ transplant waiting time in exchange for transmitting and treating Hepatitis C infection in the era of safe and effective DAAs.
     Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
     PubMed    
     
     
     August 2017
197. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
     The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
     Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
     PubMed     Abstract available
     
     
     
198. ABRAHAM GM, Spooner LM
     Citius Altius Fortius: The New Paradigm In The Treatment Of Chronic Hepatitis C Disease.
     Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
     PubMed     Abstract available
     
     
     
199. KOUAME GM, Boyd A, Moh R, Badje A, et al
     Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
     Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
     PubMed     Abstract available
     
     
     
200. WANG H, Wan Z, Xu R, Guan Y, et al
     A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
     Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
     Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
     Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. LO RE V 3RD
     Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
     Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
     PubMed    
     
     
     
203. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
     Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
     Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2017
204. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
     Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
     Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
     PubMed     Abstract available
     
     
     
205. POWDERLY WG, Naggie S, Kim AY, Vargas HE, et al
     IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
     Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
     PubMed    
     
     
     June 2017
206. CHI H, Wong D, Peng J, Cao J, et al
     Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
     Clin Infect Dis. 2017 Jun 1. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2017
207. KIM AY
     The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.
     Clin Infect Dis. 2017 May 27. doi: 10.1093.
     PubMed    
     
     
     
208. FELD JJ, Ramji A, Shafran SD, Willems B, et al
     Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
     Clin Infect Dis. 2017 May 23. doi: 10.1093.
     PubMed     Abstract available
     
     
     
209. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
     How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
     Clin Infect Dis. 2017 May 16. doi: 10.1093.
     PubMed    
     
     
     
210. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
     Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
     Clin Infect Dis. 2017 May 16. doi: 10.1093.
     PubMed    
     
     
     
211. MOON J, Hyland RH, Zhang F, Brainard DM, et al
     Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
     Clin Infect Dis. 2017 May 13. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2017
212. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
     Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
     Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. OZARAS R, Balkan II, Yemisen M, Mete B, et al
     Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
     Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
     PubMed    
     
     
     
214. BUTT AA, Yan P, Chew KW, Currier J, et al
     Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
     Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
     PubMed     Abstract available
     
     
     
215. TIEN PC
     HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
     Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
     PubMed    
     
     
     
216. CANARY L, Hariri S, Campbell C, Young R, et al
     Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
     Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
     PubMed     Abstract available
     
     
     
217. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
     Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
     Clin Infect Dis. 2017;64:860-869.
     PubMed     Abstract available
     
     
     
218. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
     Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
     Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2017
219. WYLES D, Brau N, Kottilil S, Daar ES, et al
     Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
     Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
     PubMed     Abstract available
     
     
     
220. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
     Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
     Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
     PubMed     Abstract available
     
     
     
221. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
     Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
     Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
     PubMed     Abstract available
     
     
     
222. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
     Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
     Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2017
223. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
     Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
     Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
     PubMed     Abstract available
     
     
     
224. VINIKOOR MJ, Sinkala E, Chilengi R, Mulenga L, et al
     Impact of antiretroviral therapy on liver fibrosis among HIV-infected adults with and without HBV coinfection in Zambia.
     Clin Infect Dis. 2017 Feb 4. doi: 10.1093.
     PubMed    
     
     
     August 2016
225. WITTKOP L
     Endstage liver disease in HIV infection: an avoidable burden?
     Clin Infect Dis. 2016.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: